12:47 PM
 | 
Jul 10, 2018
 |  BC Extra  |  Company News

Adlai Nortye gets rights to Novartis' buparlisib

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed.

Adlai Nortye has global rights to...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >